- Raw materials
- Vitamin D analogues
- Elocalcitol
Elocalcitol API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Elocalcitol | CAS No: 199798-84-0 | GMP-certified suppliers
A medication that is under investigation for managing benign prostatic hyperplasia, urinary incontinence, prostate disorders, and infertility with potential benefits in prostate cell growth modulation.
Therapeutic categories
Primary indications
- Investigated for use/treatment in benign prostatic hyperplasia, urinary incontinence, prostate disorders, and infertility
Product Snapshot
- Elocalcitol is a small molecule formulation intended for oral administration
- It is primarily investigated for urological and reproductive system disorders including benign prostatic hyperplasia and urinary incontinence
- The compound is currently in the investigational stage with no approved status from major regulatory authorities
Clinical Overview
The compound’s pharmacological profile targets the modulation of prostate cell growth, which is pertinent to its investigation in BPH patients. While specific pharmacodynamics and detailed mechanism of action data have not been fully disclosed, it is understood that Elocalcitol exerts effects similar to calcitriol analogs, potentially influencing cell differentiation and proliferation via vitamin D receptor-mediated pathways.
Elocalcitol remains in the investigational stage and has not received regulatory approval for commercial use. Its classification encompasses secosteroids and related steroid categories, denoting its lipid-soluble, membrane-associated properties.
Key ADME parameters such as absorption, distribution, metabolism, and elimination have not been comprehensively defined in publicly available sources. Given its structural relation to vitamin D analogs, hepatic metabolism via cytochrome P450 enzymes and renal excretion may be involved, but precise data require further elucidation.
Safety and toxicity profiles are not extensively characterized. As with other vitamin D derivatives, there may be potential concerns related to calcium metabolism and hypercalcemia, warranting careful evaluation during clinical development.
Elocalcitol has been studied in phase II clinical trials, especially focusing on its effects in BPH patients. Currently, it is not marketed under any notable brand names.
From a sourcing perspective, API procurement must ensure compliance with strict quality standards due to the compound’s investigational status and potential therapeutic application. Purity, stability, and consistency are critical parameters, with attention to regulatory guidelines governing vitamin D analog intermediates. Suppliers should provide comprehensive documentation to support regulatory submissions and ensure traceability throughout the supply chain.
Identification & chemistry
| Generic name | Elocalcitol |
|---|---|
| Molecule type | Small molecule |
| CAS | 199798-84-0 |
| UNII | 2WDS5F2V6Q |
| DrugBank ID | DB06194 |
Pharmacology
Targets
| Target | Organism | Actions |
|---|---|---|
| Vitamin D3 receptor | Humans |
Formulation & handling
- Elocalcitol is a small molecule vitamin D derivative suitable for oral formulations due to low water solubility and high lipophilicity.
- Formulation strategies should address its poor aqueous solubility, potentially requiring solubilizing agents or lipid-based delivery systems.
- Stability considerations include protection from light and moisture to maintain compound integrity during processing and storage.
Regulatory status
Elocalcitol is a type of Vitamin D analogues
Vitamin D analogues belong to the pharmaceutical category of active pharmaceutical ingredients (APIs) and are widely used in the medical field. These analogues are synthetic compounds designed to mimic the effects of natural vitamin D, a vital nutrient for human health. Vitamin D plays a crucial role in maintaining proper bone health, regulating calcium and phosphorus levels, and supporting the immune system.
Pharmaceutical companies produce various types of vitamin D analogues, each with distinct properties and applications. These analogues are designed to target specific receptors in the body, mimicking the actions of natural vitamin D. By interacting with these receptors, vitamin D analogues can effectively regulate calcium absorption and metabolism, promoting optimal bone health.
One of the significant advantages of using vitamin D analogues as APIs is their enhanced stability and bioavailability compared to natural vitamin D. This allows for better control over dosage and ensures consistent therapeutic effects. Moreover, pharmaceutical-grade analogues undergo rigorous quality control measures to guarantee their purity, safety, and efficacy.
Medical professionals prescribe vitamin D analogues to patients with vitamin D deficiencies, osteoporosis, psoriasis, and other related conditions. These APIs are available in various formulations, including oral tablets, capsules, and topical creams, allowing for flexible and convenient administration.
In summary, vitamin D analogues are a vital category of pharmaceutical APIs widely used to address vitamin D deficiencies and related health conditions. Their synthetic nature, enhanced stability, and targeted actions make them an effective option for maintaining bone health and supporting overall well-being.
